AARDVARK THERAPEUTICS, INC.
Last · —$3.88-0.16 (-3.96%)live · yahoo · 1s ago
Market cap$84.91M21.9M sh
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$3.48$15.82
Volume126.1Ksession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-23
- Operating Cf Burn
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Runway Low — Cash runway ~0.9 years
- Accumulated Deficit High — Accumulated deficit / equity 109%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.75
Est. revenue
0
Press & signals
- GlobeNewswire
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
- GlobeNewswire
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates